Ecallantide: Difference between revisions
Kurtucla05 (talk | contribs) (Created page with "==General== *Type: Kallikrein inhibitor for angioedema *Dosage Forms: 30mg *Routes of Administration: SQ *Common Trade Names: Kalbitor ==Adult Dosing== *30mg SQ *Max 60mg/ 2...") |
Ostermayer (talk | contribs) (Text replacement - "Category:Drugs" to "Category:Pharmacology") |
||
| Line 50: | Line 50: | ||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category: | [[Category:Pharmacology]] | ||
Revision as of 15:54, 22 March 2016
General
- Type: Kallikrein inhibitor for angioedema
- Dosage Forms: 30mg
- Routes of Administration: SQ
- Common Trade Names: Kalbitor
Adult Dosing
- 30mg SQ
- Max 60mg/ 24 hr
Pediatric Dosing
- acute hereditary angioedema >12yo
- 30mg SQ
Special Populations
- Pregnancy Rating:C
- Lactation risk:Safety Unknown
- Renal Dosing
- Hepatic Dosing
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- anaphylaxis
- hypersensitivity reaction
Common
- headache
- nausea
- fatigue
- diarrhea
- URI
- injection site rxn
- nasopharyngitis
- vomiting
- pruritus
- abdominal pain
- fever
- anaphylaxis
Pharmacology
- Half-life: 2h
- Metabolism: CYP450
- Excretion: Urine
- Mechanism of Action: selectively, reversibly inhibits plasma kallikrein, preventing bradykinin generation
Comments
- Plasma kallikrein works as cofactor to formation of bradykinin which is implicated in angioedema